Strife intensifies: Jörgensen ousted as Novo Nordisk's CEO

Troubles Ahead for Novo Nordisk: CEO Steps Down amidst Stock Plunge and Intense Rivalry

Strife intensifies: Jörgensen ousted as Novo Nordisk's CEO

Hang onto your stocks, folks! The CEO of Danish pharmaceutical giant, Novo Nordisk, Lars Fruergaard Jørgensen, is packing his bags. Announcing a 'mutual agreement', Novo Nordisk's board gave Jørgensen the big heave-ho. Citing "recent challenges" and the "development of the stock price since mid-2024" as the reasons, the company confirmed that the stock value has plummeted by more than half since the dude hit the exit door.

Under Jørgensen's rule, Novo Nordisk became Europe's most valuable company, thanks to its shred-pounds superstars, Ozempic, and Wegovy. Over eight years, ol' Jørgensen "tripled revenue, profit, and stock price", the company boasted. Last year, Denmark's government was so thrilled with Novo's success that they jacked up their country's growth forecasts like there's no tomorrow.

But, it seems, good times never last. Competitors have caught up, and Eli Lilly is perched to throw a wrench in the works with a cheaper, easier-to-swallow weight loss pill. Orforglipron, Eli Lilly's diabetes type 2 treatment, is also said to double as a weight loss aid - just in time for summer!

Faced with fierce competition, Novo Nordisk dropped their revenue prediction for 2025 from a whopping 21% to a more modest 13-21%. They blame the slump on generic versions of Wegovy and Ozempic launched by U.S. pharmacies. But don't worry, the U.S. authorities have called an end to the shortage and demanded the production to halt. For the first quarter, however, they reported a 19% surge in revenue and a 14% boost in profit.

Now, Novo Nordisk is on a wild goose chase for a new CEO to replace Jørgensen, who has been leading the company since 1991. He'll stick around during a transition period to ensure a smooth escape.

EconomyNovo Nordisk's shares have plummeted, leaving a nasty taste in investors' mouths. The company has slammed on the brakes, expecting revenue growth of only 13-21% in 2025. While they blame the dip on competition from generic copies of Wegovy and Ozempic produced in U.S. pharmacies, the U.S. Food and Drug Administration has ordered them to halt production, claiming the shortage is over.

Source: ntv.de, jwu/AFP/DJ

• Denmark
• Novo Nordisk
• Weight Loss Injection
• Pharmaceutical Industry

ScuttlebuttThe search is underway for Jørgensen's successor at Novo Nordisk, with no announcements as yet[1][3][4].

• The community is eagerly awaiting the announcement of Novo Nordisk's new CEO, following the departure of Lars Fruergaard Jørgensen.
• In light of the pharmaceutical industry's intense rivalry and the emergence of cheaper weight loss alternatives, Novo Nordisk is exploring vocational training programs to enhance their research and development capabilities.
• As Novo Nordisk grapples with challenging times, the health-and-wellness sector anticipates potential implications on finance and business, given the company's significant role in the pharmaceutical industry and Denmark's economy.

Read also: